FDA’s Postmarketing Powers Force Shionogi To Withdraw Rybix ODT

Agency says Shionogi’s orally disintegrating tramadol is misbranded because the firm did not submit a post-marketing trial protocol in time, but the company states the trial is not worth the expense and will withdraw the product.